Neurocrine Bioscienc (NBIX)
$109.51 2.70 (2.53%)
16:31 EST NBIX Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 9.84B
PE Ratio -92.03
Volume (Avg. Vol.) 1.29M
Day's Range 105.58 - 110.49
52-Week Range 72.14 - 136.26
Dividend & Yield N/A (N/A)
NBIX Stock Predictions, Articles, and Neurocrine Bioscienc News
- From InvestorPlace
- From the Web
Investors seeking strong growth companies to invest in should watch Credit Acceptance Corporation, RenaissanceRe and Neurocrine Biosciences.
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Neurocrine Biosciences, Facebook and Etsy are just some of the stocks to buy if you want growth because they're outpacing Amazon.
These 10 smart money stocks to buy have significant support from top analysts. Here's why each should help you flourish throughout the rest of the year.
Looking for stocks to buy now? These six companies are among the best stocks to invest in for their immaculate record from the Street's top analysts. Here's why:
Biopharma company Neurocrine isn't letting a setback with one of its drugs stop it. Here's what to know about NBIX stock.
A slow summer puts a premium on fast-growing stocks, and even more so on names that are headed into some splashy headlines.
3 Stocks to Watch on Wednesday: Tesla, Inc. (TSLA), Delta Air Lines, Inc. (DAL) and Neurocrine Biosciences, Inc. (NBIX)
Delta Air Lines (DAL) pops on solid Q1 earnings, a major investor questions Tesla's (TSLA) board and Neurocrine Biosciences (NBIX) is flying on an FDA approval.
These small-cap stocks all have the potential to dish out misery, but if things work out just right, look out above.
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The ratings of 26 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The following stocks were moving the Manufacturing sector today.
This week, 9 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
Navellier RatingsPowered by Portfolio Grader